| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, Oviedo, Spain
Correspondence
Carmen Méndez
cmendezf{at}uniovi.es
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
). The agents inhibit growth and multiplication of several tumour cell lines, and they also act on Gram-positive bacteria. Some of the members of this family have clinical applications, and they are used for the treatment of certain tumours, such as disseminated embryonal cell carcinoma and Paget's bone disease, and also for the control of hypercalcaemia in patients with malignant diseases (Remers, 1979; Skarbek & Speedie, 1981). More recently, chromomycin and mithramycin have been found to stimulate K562 cell erythroid differentiation (Bianchi et al., 1999), and both drugs have been suggested as potential neurological therapeutics (Chatterjee et al., 2001), and for use in the treatment of HIV-1 (Bianchi et al., 1997). The antitumour properties of these compounds are ascribed to their inhibitory effects on replication and transcription processes during macromolecular biosynthesis by interacting, in the presence of Mg2+, with GC-rich nucleotide sequences located in the minor groove of DNA (Sastry & Patel, 1993; Sastry et al., 1995; Barcelo et al., 2007).
Structurally, the aureolic acid compounds belong to the large and important family of the aromatic polyketides. All members of the group (with the exception of chromocyclomycin) consist of a tricyclic chromophore that has one or two aliphatic side chains (aglycone), and which is glycosylated at two different positions with saccharide chains of variable length. Mithramycin and chromomycin A3 (Fig. 1) share the same aglycone, and they differ only in some of the sugars attached to it (Wohlert et al., 1999). The gene clusters involved in the biosynthesis of mithramycin (Blanco et al., 1996, 2000; Fernández et al., 1998; Lozano et al., 2000; González et al., 2001; Lombó et al., 1996, 1997; Prado et al., 1999) and chromomycin A3 have been cloned and characterized (Menéndez et al., 2004a, b, 2006). Interestingly, although there is high similarity between most individual mithramycin and chromomycin genes, the arrangement of genes in both clusters is organized in a substantially different way (Menéndez et al., 2004a). It has also been reported that the producer organisms of these two compounds, Streptomyces argillaceus ATCC 12956 (mithramycin producer) and Streptomyces griseus subsp. griseus ATCC 13273 (chromomycin A3 producer), are naturally highly resistant to their own produced antibiotic, but, despite the close structural similarity between these two drugs, they do not show cross-resistance (Fernández et al., 1996). In the mithramycin producer, the main resistant determinant is a type I ABC (ATP-binding cassette) transporter system (Méndez & Salas, 2001) encoded by the mtrA and mtrB genes; the system is able to confer high level of resistance to mithramycin, but not to chromomycin (Fernández et al., 1996). Analysis of the chromomycin gene cluster revealed, as a putative self-resistance mechanism, two genes encoding an ABC transporter system, and a gene encoding an UvrA-like protein of ABC excision nuclease systems that are responsible for DNA repair (Menéndez et al., 2004a).
|
|
METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
). For sporulation on solid medium, the organisms were grown at 30 °C on plates containing A medium (Fernández et al., 1998). For growth in liquid medium, the organisms were grown either in TSB medium (trypticase soya broth; Oxoid) or in R5A medium (Fernández et al., 1998). Streptomyces albus J1074 (ilv-1, sal-2; Kieser et al., 2000) was used as host for expression of chromomycin genes. Escherichia coli DH10B (Invitrogen) was used as a host for subcloning. E. coli ET12567 (pUB307; Kieser et al., 2000) was used as donor for intergeneric conjugation. When plasmid-containing clones were grown, the medium was supplemented with the appropriate antibiotics: 5 or 25 µg thiostrepton ml–1 for liquid or solid cultures, respectively; 100 µg ampicillin ml–1; 25 µg apramycin ml–1; 20 µg tobramycin ml–1, 25 µg kanamycin ml–1; and 25 µg chloramphenicol ml–1. pUC18, pHZ1358 (Kieser et al., 2000), pUK21 (Vieira & Messing, 1991) and pIJ2925 (Kieser et al., 2000) were used for subcloning. pWHM3 (Kieser et al., 2000) and pEM4 (Quirós et al., 1998) were used for expression in S. albus. cosGR10 was used as a source of DNA (Menéndez et al., 2004a).
DNA manipulation.
Plasmid DNA preparations, restriction endonuclease digestions, alkaline phosphatase treatments, DNA ligations, Southern hybridization, and other DNA manipulations, were performed according to standard techniques for E. coli (Sambrook et al., 1989) and Streptomyces (Kieser et al., 2000). Preparation of S. albus protoplasts, and transformation and selection of transformants, were carried out as described (Kieser et al., 2000). Intergeneric conjugation from E. coli ET12567 (pUB307) to S. griseus subsp. griseus was performed as described (Kieser et al., 2000). Computer-aided database searching and sequence analysis were carried out using the University of Wisconsin Genetics Computer Group program package and the BLAST program.
Plasmid constructs
Several constructs (Fig. 2a) were generated in order to localize the chromomycin-resistance determinant, as described below. All the constructs were introduced by protoplast transformation into S. albus, and transformants were selected for thiostrepton resistance.
|
pNM30 (cmmRII, cmrA and cmrB genes): a 4.6 kb PstI fragment from cosGR10 (one of the restriction sites derived from the vector), including cmmRII, cmrA, cmrB and the 5' end of cmrX, was subcloned into the PstI site of pEM4; in this construct, the ermEp promoter controls expression of cmmRII, cmrA and cmrB.
pNM34 (cmrX, cmmRII, cmrA and cmrB genes): a 4.2 kb BamHI fragment containing the 5' end of cmmRII, cmrX and cmmC was subcloned into the same site of pUC18; this construct, pNC60A, was then digested with PstI (there is a PstI site within cmrX, and another in the polylinker), and a 4.6 kb PstI fragment from cosGR10 (one site derived from the vector), containing cmmRII, cmrA, cmrB and the 5' end of cmrX, was inserted in the correct orientation; the whole insert in pUC18 was finally rescued as a 7.3 kb HindIII–EcoRI fragment (using these sites from the polylinker), and subcloned into the same sites of pWHM3, generating pNM34.
pNM39 (cmmRII and cmrX genes): a 4.2 kb NcoI–NdeI fragment, including cmmRII, cmrX and the 5' end of cmrA, was subcloned into the same sites of pUK21, generating pUK39; a SpeI fragment was rescued (using these sites from the polylinker), and subcloned into the XbaI site of pWHM3.
pNM42 (cmrX gene): a 4.2 kb BamHI fragment, containing cmrX and the 5' end of cmmRII, was subcloned from pNC60A into the same site of pEM4, downstream of the ermEp promoter.
pNM46 (cmrA, cmrB and cmrX genes): a 2.1 kb XbaI–HindIII (both sites blunt-ended) fragment from pNM28, containing cmrA and cmrB under the control of ermEp, was subcloned into the HindIII site (blunt-ended) of pNM42; in this construct, cmrX is divergently transcribed to cmrA and cmrB genes.
Generation of mutants
For the generation of mutant C60RII, plasmid pC60RII was constructed as follows (Fig. 3a). A 2.65 kb PstI–BglII fragment (this last site was derived from the polylinker) of pUK39, containing cmmRII and the 5' ends of cmrA and cmrX, was subcloned into the PstI and BamHI sites of pUC18, generating pUR2. Then, a BamHI–HindIII fragment (blunt-ended), containing an apramycin-resistance cassette, was inserted into the unique BamHI site (blunt-ended) of pUR2 located within cmmRII, and in the same direction of transcription, generating pUR2A. Afterwards, the whole insert was rescued from pUR2A as an EcoRI–HindIII fragment (using these sites from the polylinker), and subcloned into the same sites of pIJ2925, generating pJR2A. Finally, the complete insert was subcloned as a BglII fragment (using these sites from the polylinker) into the BamHI site of pHZ1358, generating pC60RII. This construct was introduced by intergeneric conjugation into S. griseus, and apramycin-resistant thiostrepton-sensitive transconjugants were selected for further characterization.
|
). pNC60A was digested with NotI, which cuts twice within cmrX, then treated with Klenow polymerase, and ligated to a HindIII–BamHI fragment (blunt-ended) containing the apramycin-resistance cassette, generating pXA. The whole fragment was rescued from pXA as a BamHI fragment, and subcloned into the same site of pHZ1358, generating pC60X. This construct was introduced by intergeneric conjugation into S. griseus, and apramycin-resistant thiostrepton-sensitive transconjugants were selected for further characterization.
|
Determination of chromomycin A3 production.
Chromomycin A3 production by S. griseus wild-type (WT) and mutant strains was determined as follows. A seed culture was prepared in TSB medium, and inoculated with a spore suspension. After incubation for 24 h at 30 °C and 250 r.p.m., the culture was used to inoculate (at 2 %, v/v) 250 ml flasks containing 50 ml R5A medium. Production of chromomycin A3 was monitored daily for 7 days, as follows: 1 ml samples were centrifuged at 14 000 r.p.m. in an Eppendorf centrifuge (model no. 5417) for 2 min, and 200 µl of the supernatant was used to test for chromomycin A3 production by using HPLC. Samples (10 µl) were analysed for chromomycin A3 using a Symmetry C18 column (Waters), and isocratic elution with a mixture of 40 % acetonitrile and 60 % water, acidified with 0.1 % TFA, at a flow rate of 1 ml min–1. Detection and spectral characterization of peaks were performed with a photodiode array detector (Waters). Measurement of peak areas, and comparison with known concentrations of chromomycin, was used to estimate chromomycin A3 concentrations. For each experiment, two independent cultures were run and analysed.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
). An indication of the involvement of this ABC transporter system in chromomycin resistance was first obtained when several cosmid constructs coming from a gene library of S. griseus, and harbouring the cmrA and cmrB genes, were expressed in the chromomycin-sensitive strain S. albus, rendering recombinant strains resistant to high levels of chromomycin A3 (MIC >100 µg ml–1) (Fig. 2a
). To confirm that the ABC transporter genes were responsible for this phenotype, we expressed the cmrA and cmrB genes, under the control of the constitutive erythromycin-resistance promoter ermE*p (pNM28) (Fig. 2b), in S. albus, and we compared the susceptibility to chromomycin A3 of this recombinant strain (strain NM28) with that of S. albus harbouring the vector only (strain EM4). We found that the chromomycin ABC transporter conferred a low level of resistance to chromomycin A3 (MIC 20 µg ml–1) in comparison with that conferred by the vector (MIC 2.5 µg ml–1). These experiments indicate that the ABC transporter genes alone do not account for the high level of resistance shown by the chromomycin producer. Therefore, other genes must participate in self-resistance to chromomycin in S. griseus, and these could be harboured in cosmids, thus conferring a high level of resistance to chromomycin A3 to other hosts.
Strain NM28 was also tested for mithramycin resistance. Surprisingly, it was found to show a high level of resistance to mithramycin (MIC >100 µg ml–1). This result was an apparent contradiction to earlier reports that have indicated that the chromomycin producer is sensitive to mithramycin, i.e. S. griseus (chromomycin producer) was unable to grow in the presence of mithramycin (Fernández et al., 1996). Since, in the present experiment, the cmrA and cmrB genes were under the control of a constitutive promoter, we wondered whether the lack of resistance to mithramycin previously observed in the chromomycin producer had been due to the absence of expression of the ABC transporter genes in the conditions tested. We hypothesized that, perhaps, in the chromomycin producer, expression of the chromomycin-resistance genes could be induced during chromomycin production, as this has been shown to occur for other resistance determinants in producer organisms (Pernodet et al., 1993; Vilches et al., 1990). To test this hypothesis, we assayed mithramycin resistance in S. griseus after induction with low amounts of chromomycin A3. On plates inoculated with spores of S. griseus, 20 µg chromomycin A3 was loaded onto a disc, and this was placed in the proximity of another disc containing 100 µg mithramycin. The growth inhibition halo that formed around the mithramycin disc was sharply reduced in the vicinity of the chromomycin disc, suggesting a phenomenon of induction of resistance (Fig. 5). This was verified by evaluating the growth of S. griseus on agar plates containing 100 µg ml–1 mithramycin, with and without the addition of 2 µg ml–1 chromomycin A3 as the inducer agent: the presence of chromomycin allowed normal development of the strain on mithramycin-containing agar plates, while there was no growth in the absence of chromomycin. These experiments clearly indicate that expression of the chromomycin ABC transporter in the producer organism is inducible, and that chromomycin A3 can be used as an inducer. These results also confirm that the chromomycin ABC transporter confers resistance to mithramycin. In light of these results, the apparent contradiction reported above, regarding the results reported in this paper and those of Fernández et al. (1996), is not such a great contradiction, since, in those experiments, S. griseus was exposed to mithramycin before the onset of chromomycin production. Consequently, in those conditions, the CmrAB transporter was not expressed, and therefore S. griseus could not grow.
|
, b, 2006). Two genes of the chromomycin cluster, cmrX and cmmRII, were candidates to participate in chromomycin resistance based on: (i) their location in the vicinity of cmrA and cmrB, (ii) their presence in cosmids conferring a high level of resistance to chromomycin A3, and (iii) the putative roles of the deduced gene products by database comparisons. CmrX shows high similarity to several UvrA-like proteins of ABC excision nuclease systems involved in DNA repair. It also showed similarity to MtrX, which is a protein involved in mithramycin resistance in S. argillaceus (52 % identity) (Garcia-Bernardo et al., 2000), and to DrrC, which is involved in daunorubicin resistance in Streptomyces peucetius (38.2 % identity) (Lomovskaya et al., 1996). DrrC has been shown to behave like an ATP-dependent DNA-binding protein in vitro (Furuya & Hutchinson, 1998). CmmRII showed the highest similarities to putative transcriptional regulators present in the genomes of Nocardia farcinica (accession nos YP_118862 and YP_121769), Gloeobacter violaceus (accession no. NP_924384) and Streptomyces avermitilis (accession no. BAC74016); the similarities ranged from 23 to 31 % identical amino acids, and CmmRII was shown to contain the conserved region COG1695 (predicted transcriptional regulators). CmmRII also showed similarity (25.4 % identity) to MtrY from the mithramycin cluster (Fernández et al., 1996). To test the possible requirement of one or both of these genes in conferring a high level of resistance to chromomycin A3, we subcloned a 6.8 kb fragment (Fig. 2b), containing the four genes cmrB, cmrA, cmmRII and cmrX, into pWHM3. When the corresponding construct (pNM34) was introduced into S. albus, the recombinant strain became highly resistant to chromomycin A3 (MIC >100 µg ml–1), indicating that high levels of resistance to chromomycin are most probably dependent on the simultaneous presence of cmmRII and/or cmrX, together with cmrA and cmrB. Therefore, we independently subcloned cmrA and cmrB genes in combination with either cmmRII (pNM30) or cmrX (pNM46) (Fig. 2b). In addition, constructs with cmrX alone (pNM42), or together with cmmRII (pNM39), were assayed (Fig. 2b). Only the construct pNM46, which harbours cmrA, cmrB and cmrX, conferred a high level of resistance to chromomycin A3 (MIC >100 µg ml–1). Expression of the cmrX gene alone conferred a very low level of resistance to chromomycin A3 (MIC 5 µg ml–1). These results clearly indicate that the coexpression of cmrA, cmrB and cmrX is required to confer a high level of resistance to chromomycin A3. This is in contrast to what happens in the mithramycin producer, in which expression of the two genes coding for the ABC transporter is sufficient to confer a high level of resistance to mithramycin (Fernández et al., 1996). These results also suggest that the chromomycin ABC transporter and CmrX could act in a cooperative way, since the level of resistance conferred by co-expression of the three genes is higher than the sum of resistance conferred by the CmrAB transporter or CmrX, separately.
Insertional inactivation of cmrX and cmmRII
To get further information about the roles of cmmRII and cmrX genes in the biosynthesis and resistance to chromomycin A3, we decided to inactivate each gene in S. griseus. Using gene replacement, we generated two independent mutants, in which we replaced the WT alleles in the chromosome with the alleles that had been mutated in vitro. To do this, we generated several constructs in the unstable plasmid pHZ1358, in which each gene was interrupted by an apramycin-resistance cassette, which was inserted in the direction of transcription of the targeted gene, within the corresponding coding regions. The corresponding constructs (pC60RII for cmmRII, and pC60X for cmrX) were introduced in S. griseus by intergeneric conjugation, and transconjugants, in which a double crossover had taken place, were selected for their resistance to apramycin, and susceptibility to thiostrepton. One colony from each mutant (C60RII and C60X) was selected for further analysis. For both C60RII and C60X, it was verified by Southern hybridization that the gene replacement event had taken place (Figs 3 and 4). Both mutants were then analysed for resistance to, and production of, chromomycin A3. The C60RII mutant (cmmRII mutant), showed levels of resistance to chromomycin A3 that were similar to those of the WT strain (Fig. 6a), but, surprisingly, the mutant was also very resistant to mithramycin, without the addition of chromomycin A3 to the cultures as an inducer (MIC >100 µg ml–1). Notably, production of chromomycin A3 in this mutant started earlier, and the yields were higher (about 70 % higher), than in the case of the WT strain (Fig. 7). These results suggest that CmmRII could probably act as a transcriptional repressor in chromomycin biosynthesis/resistance. In contrast, the C60X mutant (cmrX mutant) was much more sensitive to chromomycin A3 than the WT strain (Fig. 6a), and it showed a reduction in chromomycin production of about 50 % (Fig. 7). These results confirm that CmrX is implicated in chromomycin resistance, and that it is important in the self-protecting mechanism to chromomycin in S. griseus.
|
|
A chromomycin biosynthesis intermediate as a possible substrate for the ABC transporter CmrAB
As mentioned above, it was surprising that the chromomycin ABC transporter conferred a high level of resistance to mithramycin, but only low levels of resistance to chromomycin A3. This was not what was expected for a transporter system that it is supposed to export a highly potent antibiotic, such as chromomycin A3. We wondered if the chromomycin ABC transporter could recognize and secrete a biosynthesis intermediate instead of the final product chromomycin A3. It has been shown (Menéndez et al., 2004b) that the last step in chromomycin A3 biosynthesis is a sugar-tailoring modification event, consisting of the acetylation of two hydroxyl groups present in two different sugars. A single acetyltransferase CmmA is responsible for both of the events. By inactivating cmmA, the biosynthesis intermediate DDACA3 (Fig. 1) was isolated. This compound lacks two acetyl groups in sugars A and E, and shows antibiotic activity, although its activity is lower than that in the final compound. Since DDACA3 is the immediate precursor of chromomycin A3, and based on the fact that CmmA acetyltransferase is a membrane protein (B. García, N. Menéndez, J. A. Salas & C. Méndez, unpublished), we hypothesized that perhaps DDACA3 could be the actual substrate for the CmrAB ABC transporter. If this was the case, the CmrAB transporter should confer resistance to this compound. Consequently, we tested the susceptibility of S. albus recombinant strain NM28 (expressing cmrA and cmrB) to the dideacetylated intermediate, and compared the results with those for chromomycin A3 (Fig. 6). As shown in Fig. 6, S. albus NM28 was highly sensitive to chromomycin A3 (Fig. 6b), but highly resistant to DDACA3 (Fig. 6c). However, the control strain (S. albus EM4) was sensitive to both chromomycin A3 and DDACA3. In addition, we also tested the DDACA3 susceptibility of other S. albus recombinant strains expressing different combinations of cmr genes (Fig. 2b). Only those strains expressing cmrA and cmrB were highly resistant to DDACA3. These results indicate that the CmrAB ABC transporter efficiently secretes DDACA3, but not chromomycin A3. On the other hand, strains expressing cmrX, but not cmrAB, showed a low level of resistance to DDACA3, suggesting that CmrX could play a role in S. griseus in self-protection against bioactive intermediates, such as DDACA3, synthesized during the biosynthesis of chromomycin A3. In agreement with this, analysis of the susceptibility of S. griseus C60X (cmrX mutant) to DDACA3 showed that, although no inhibition of growth was observed at short incubation times, there was reduced growth over longer time periods. This effect was not observed with either the WT strain or the mutant C60RII, as both showed normal growth (data not shown).
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
; Martin et al., 2005; Méndez & Salas, 2001). The chromomycin producer S. griseus subsp. griseus is highly resistant to chromomycin A3, and the chromomycin gene cluster contains three genes (cmrA, cmrB and cmrX) that are involved in self-resistance to chromomycin A3. Genes cmrA and cmrB encode for an ABC transporter system, which is an efflux mechanism for the drug, and cmrX encodes a UvrA-like protein of ABC excision nuclease systems, which are responsible for DNA repair. Confirmation of the role of these genes in chromomycin resistance was achieved by independently or jointly expressing these genes in the chromomycin-sensitive strain S. albus. The results indicated that expression of the three genes (cmrA, cmrB and cmrX) was required to confer a high level of resistance to chromomycin A3. Expression of either cmrA and cmrB, or cmrX, resulted in a low level of resistance to chromomycin A3. Consequently, cmrAB and cmrX are two chromomycin-resistance determinants. Additional confirmation of the essential role of cmrX in self-resistance to chromomycin A3 was achieved by insertional inactivation of this gene; this resulted in the generation of a strain that was more sensitive to, and produced less of, chromomycin A3. In a similar way, we tried to inactivate cmrAB, but this was not achieved, and it suggests that mutations in these genes are lethal for the producer strain. A similar situation occurs in the mithramycin producer, in which the inactivation of the mithramycin ABC transporter was also pursued, but not achieved, in the producer strain (Fernández et al., 1998). On the basis of these results, we speculate that CmrX could be a DNA-binding protein that plays a role in self-resistance to chromomycin by inhibiting or destabilizing the interaction of chromomycin A3 (and precursors) and genomic DNA, thus preventing chromomycin from interfering with cell transcription and/or replication. A similar mechanism has also been proposed for the analogous protein DrrC, which is another UvrA-like protein from the daunorubicin gene cluster that has been shown to behave in vitro like an ATP-dependent DNA-binding protein (Furuya & Hutchinson, 1998; Lomovskaya et al., 1996). In addition, CmrX could play a regulatory role in chromomycin biosynthesis, since its absence leads to lower production yields of chromomycin. In relation to this, it has been shown that the CmrX-like protein DrrC can bind the promoter region of the regulatory gene dnrI, which is involved in daunorubicin biosynthesis (Furuya & Hutchinson, 1998). In the case of chromomycin biosynthesis, one can speculate that, in the absence of CmrX, the expression of regulatory genes could be affected. The chromomycin-resistance genes are grouped in the chromosome, together with a gene encoding a transcriptional repressor (cmmRII), which most probably plays a role as a transcriptional repressor in chromomycin resistance/biosynthesis in the producer organism. Thus, its inactivation makes S. griseus a high producer of chromomycin A3, and a strain constitutively resistant to mithramycin. However, its presence is not essential to confer resistance to chromomycin A3 in a heterologous host if the chromomycin-resistance genes are expressed under the control of a constitutive promoter, i.e. the ermEp promoter.
The chromomycin ABC transporter appears to play a major role in the self-protection system of S. griseus, since its disruption seems to be lethal to the micro-organism, and its expression in S. albus resulted in a higher level of resistance compared with the expression of cmrX. ABC transporters are frequently found in antibiotic-biosynthesis gene clusters, where they play a role in secreting the antibiotic out of the cell, thus preventing the antibiotic from acting on internal cell structures or enzymes (Fernández et al., 1996; Guilfoile & Hutchinson, 1991; Olano et al., 1995). Surprisingly, the CmrAB transporter confers a low level of resistance to chromomycin A3, but it confers a high level of resistance to the biosynthesis intermediate DDACA3; this indicates that this biosynthesis intermediate is the substrate for the CmrAB transporter. Conversion of this compound into chromomycin A3 is carried out by the action of the acetyltransferase CmmA (Menéndez et al., 2004b), which has been shown recently to be a transmembrane protein (B. García, N. Menéndez, J. A. Salas & C. Méndez, unpublished). Taking all these findings into account, we propose a model for the biosynthesis of, and self-resistance to, chromomycin A3 in S. griseus subsp. griseus, by which chromomycin biosynthesis proceeds through intermediates with weak biological activity. CmrX participates in protecting the producer against these compounds that have low bioactivity. The last intracellular product is the dideacetylated, but methylated, intermediate DDACA3. This compound, which also shows weaker antibiotic activity, is recognized by the ABC transporter CmrAB, and then acetylated by the membrane-bound CmmA, and thus converted into the fully biologically active chromomycin A3. This model of biosynthesis represents an evolutionary advantage for the producer strain to survive during antibiotic biosynthesis, since formation of the antibiotic is not completed inside the cell, but requires a final step. In this way, the organism avoids the interaction of the harmful compound chromomycin A3 with its intracellular target. In some macrolide producers, such as Streptomyces antibioticus (oleandomycin producer) and Streptomyces venezuelae (methymycin producer), the active compounds are not found inside the cell; however, in these micro-organisms, the situation is rather different to the chromomycin producer, since the biosynthesis of the antibiotics is actually completed inside the cell, but the antibiotics are modified by glycosylation to render them inactive, and they are then activated once they are outside the cell (Quirós et al., 1998; Zhao et al., 2003). In contrast, in the chromomycin producer, formation of the fully active compound requires the incorporation of additional functional groups (i.e. acetyl groups) to DDACA3, and this probably occurs during the secretion process. Studies now in progress are focused on determining the affinity of the ABC transporter by the deacetylated intermediate, and on elucidating the possible interaction between the ABC transporter and the acetyltransferase CmmA.
|
ACKNOWLEDGEMENTS |
|---|
Edited by: J. Anné
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
Bianchi, N., Rutigliano, C., Passadore, M., Tomassetti, M., Pippo, L., Mischiati, C., Feriotto, G. & Gambari, R. (1997). Targeting of the HIV-1 long terminal repeat with chromomycin potentiates the inhibitory effects of a triplex-forming oligonucleotide on Sp1-DNA interactions and in vitro transcription. Biochem J 326, 919–927.[Medline]
Bianchi, N., Osti, F., Rutigliano, C., Corradini, F. G., Borsetti, E., Tomassetti, M., Mischiati, C., Feriotto, G. & Gambari, R. (1999). The DNA-binding drugs mithramycin and chromomycin are powerful inducers of erythroid differentiation of human K562 cells. Br J Haematol 104, 258–265.[CrossRef][Medline]
Blanco, G., Fu, H., Mendez, C., Khosla, C. & Salas, J. A. (1996). Deciphering the biosynthetic origin of the aglycone of the aureolic acid group of anti-tumor agents. Chem Biol 3, 193–196.[CrossRef][Medline]
Blanco, G., Fernández, E., Fernández, M. J., Braña, A. F., Weißbach, U., Künzel, E., Rohr, J., Méndez, C. & Salas, J. A. (2000). Characterization of two glycosyltransferases involved in early glycosylation steps during biosynthesis of the antitumor polyketide mithramycin by Streptomyces argillaceus. Mol Gen Genet 262, 991–1000.[CrossRef][Medline]
Chatterjee, S., Zaman, K., Ryu, H., Conforto, A. & Ratan, R. R. (2001). Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Ann Neurol 49, 345–354.[CrossRef][Medline]
Cundliffe, E. (1989). How antibiotic-producing organisms avoid suicide. Annu Rev Microbiol 43, 207–233.[CrossRef][Medline]
Fernández, E., Lombó, F., Méndez, C. & Salas, J. A. (1996). An ABC transporter is essential for resistance to the antitumor agent mithramycin in the producer Streptomyces argillaceus. Mol Gen Genet 251, 692–698.[Medline]
Fernández, E., Weibbach, U., Sánchez Reillo, C., Braña, A. F., Méndez, C., Rohr, J. & Salas, J. A. (1998). Identification of two genes from Streptomyces argillaceus encoding two glycosyltransferases involved in the transfer of a disaccharide during the biosynthesis of the antitumor drug mithramycin. J Bacteriol 180, 4929–4937.
Furuya, K. & Hutchinson, C. R. (1998). The DrrC protein of Streptomyces peucetius, a UvrA-like protein, is a DNA-binding protein whose gene is induced by daunorubicin. FEMS Microbiol Lett 168, 243–249.[CrossRef][Medline]
Garcia-Bernardo, J., Braña, A. F., Mendez, C. & Salas, J. A. (2000). Insertional inactivation of mtrX and mtrY genes from the mithramycin gene cluster affects production and growth of the producer organism Streptomyces argillaceus. FEMS Microbiol Lett 186, 61–65.[CrossRef][Medline]
González, A., Remsing, L. L., Lombó, F., Fernández-Lozano, M. J., Prado, L., Braña, A. F., Rohr, J., Méndez, C. & Salas, J. A. (2001). The mtmCUV genes of the antitumor mithramycin gene cluster are involved in the biosynthesis of the sugar moieties. Mol Gen Genet 264, 827–835.[CrossRef][Medline]
Guilfoile, P. G. & Hutchinson, C. R. (1991). A bacterial analog of the mdr gene of mammalian tumor cells is present in Streptomyces peucetius, the producer of daunorubicin and doxorubicin. Proc Natl Acad Sci U S A 88, 8553–8557.
Kieser, T., Bibb, M. J., Buttner, M. J., Chater, K. F. & Hopwood, D. A. (2000). Practical Streptomyces Genetics. Norwich, UK: The John Innes Foundation.
Lombó, F., Blanco, G., Fernández, E., Méndez, C. & Salas, J. A. (1996). Characterization of Streptomyces argillaceus genes encoding a polyketide synthase involved in the biosynthesis of the antitumor mithramycin. Gene 172, 87–91.[CrossRef][Medline]
Lombó, F., Siems, K., Braña, A. F., Méndez, C., Bindseil, K. & Salas, J. A. (1997). Cloning and insertional inactivation of Streptomyces argillaceus genes involved in earliest steps of sugar biosynthesis of the antitumor polyketide mithramycin. J Bacteriol 179, 3354–3357.
Lomovskaya, N., Hong, S. K., Kim, S. U., Fonstein, L., Furuya, K. & Hutchinson, C. R. (1996). The Streptomyces peucetius drrC gene encodes a UvrA-like protein involved in daunorubicin resistance and production. J Bacteriol 178, 3238–3245.
Lozano, M. J., Remsing, L. L., Quirós, L. M., Braña, A. F., Fernández, E., Sánchez, C., Méndez, C., Rohr, J. & Salas, J. A. (2000). Characterization of two polyketide methyltransferases involved in the biosynthesis of the antitumor drug mithramycin by Streptomyces argillaceus. J Biol Chem 275, 3065–3074.
Martin, J. F., Casqueiro, J. & Liras, P. (2005). Secretion systems for secondary metabolites: how producer cells send out messages of intercellular communication. Curr Opin Microbiol 8, 282–293.[CrossRef][Medline]
Méndez, C. & Salas, J. A. (2001). The role of ABC transporters in antibiotic-producing organisms: drug secretion and resistance mechanism. Res Microbiol 152, 341–350.[Medline]
Menéndez, N., Mohammad, N., Braña, A. F., Rohr, J., Salas, J. A. & Méndez, C. (2004a). Biosynthesis of the antitumor chromomycin A3 in Streptomyces griseus: analysis of the gene cluster and rational design of novel chromomycin analogues. Chem Biol 11, 21–32.[CrossRef][Medline]
Menéndez, N., Nur-e-Alam, M., Braña, A. F., Rohr, J., Salas, J. A. & Méndez, C. (2004b). Tailoring modification of deoxysugars during biosynthesis of the antitumor drug chromomycin A3 by Streptomyces griseus subsp. griseus. Mol Microbiol 53, 903–915.[CrossRef][Medline]
Menéndez, N., Nur-e-Alam, M., Fischer, C., Braña, A. F., Salas, J. A., Rohr, J. & Méndez, C. (2006). Deoxysugar transfer during chromomycin A3 biosynthesis in Streptomyces griseus subsp. griseus: new derivatives with antitumor activity. Appl Environ Microbiol 72, 167–177.
Olano, C., Rodríguez, A. M., Méndez, C. & Salas, J. A. (1995). A second ABC transporter is involved in oleandomycin resistance and its secretion by Streptomyces antibioticus. Mol Microbiol 16, 333–343.[CrossRef][Medline]
Pernodet, J. L., Alegre, M. T., Blondelet-Rouault, M. H. & Guerineau, M. (1993). Resistance to spiramycin in Streptomyces ambofaciens, the producer organism, involves at least two different mechanisms. J Gen Microbiol 139, 1003–1011.
Prado, L., Lombó, F., Braña, A. F., Méndez, C., Rohr, J. & Salas, J. A. (1999). Analysis of two chromosomal regions adjacent to a type II polyketide synthase involved in the biosynthesis of the antitumor polyketide mithramycin in Streptomyces argillaceus. Mol Gen Genet 261, 216–225.[CrossRef][Medline]
Quirós, L. M., Aguirrezabalaga, I., Olano, C., Méndez, C. & Salas, J. A. (1998). Two glycosyltransferases and a glycosidase are involved in oleandomycin modification during its biosynthesis by Streptomyces antibioticus. Mol Microbiol 28, 1177–1186.[CrossRef][Medline]
Remers, W. A. (1979). The Chemistry of Antitumor Antibiotics, vol. 1, pp. 133–175. New York: Wiley Interscience.
Rohr, J., Méndez, C. & Salas, J. A. (1999). The biosynthesis of aureolic acid group antibiotics. Bioorg Chem 27, 41–54.[CrossRef]
Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989). Molecular Cloning: a Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
Sastry, M. & Patel, D. J. (1993). Solution structure of the mithramycin dimer–DNA complex. Biochemistry 32, 6588–6604.[CrossRef][Medline]
Sastry, M., Fiala, R. & Patel, D. J. (1995). Solution structure of mithramycin dimers bound to partially overlapping sites on DNA. J Mol Biol 251, 674–689.[CrossRef][Medline]
Skarbek, J. D. & Speedie, M. K. (1981). Antitumor Compounds of Natural Origin, vol. 1, pp. 191–235. Edited by A. Aszalos. Boca Raton, FL: CRC Press.
Vieira, J. & Messing, J. (1991). New pUC-derived cloning vectors with different selectable markers and DNA replication origins. Gene 100, 189–194.[CrossRef][Medline]
Vilches, C., Méndez, C., Hardisson, C. & Salas, J. A. (1990). Biosynthesis of oleandomycin by Streptomyces antibioticus: influence of nutritional conditions and development of resistance. J Gen Microbiol 136, 1447–1454.
Wohlert, S. E., Kunzel, E., Machinek, R., Mendez, C., Salas, J. A. & Rohr, J. (1999). The structure of mithramycin reinvestigated. J Nat Prod 62, 119–121.[CrossRef][Medline]
Zhao, L., Beyer, N. J., Borisova, S. A. & Liu, H. W. (2003). β-Glucosylation as a part of self-resistance mechanism in methymycin/pikromycin producing strain Streptomyces venezuelae. Biochemistry 42, 14794–14804.[CrossRef][Medline]
Received 8 March 2007;
revised 17 May 2007;
accepted 4 June 2007.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
